@article{98bea9c85dfe44ceb52f11813f16878c,
title = "Semaglutide and cardiovascular outcomes by baseline HbA1c in diabetes: the SUSTAIN 6 and PIONEER 6 trials",
keywords = "Cardiovascular System, Diabetes Mellitus, Type 2/complications, Glucagon-Like Peptides/therapeutic use, Glycated Hemoglobin, Humans, Hypoglycemic Agents/therapeutic use, Type 2 diabetes, HbA, Semaglutide, Major adverse cardiovascular events, Glucagon-like peptide-1 receptor agonist, PIONEER 6, Cardiovascular outcomes trial, Post hoc analysis, SUSTAIN 6",
author = "Mellbin, \{Linda G\} and Bhatt, \{Deepak L\} and Jens-Peter David and Kathrine Ekstr{\"o}m and Petrie, \{Mark C\} and S{\o}ren Rasmussen and Tina Vilsb{\o}ll",
year = "2024",
month = apr,
day = "14",
doi = "10.1093/eurheartj/ehae028",
language = "English",
volume = "45",
pages = "1371--1374",
journal = "European Heart Journal",
issn = "0195-668X",
publisher = "Oxford University Press",
number = "15",
}